Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients

(2011) J. Maringwa et al.   ANNALS OF ONCOLOGY

Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival

(2011) Chantal Quinten et al.   JNCI-Journal of the National Cancer Institute

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

(2011) J. S. Wefel et al.   NEURO-ONCOLOGY

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer

(2010) Jeffrey S. Wefel et al.   CANCER

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

(2010) Martin J.B. Taphoorn et al.   EUROPEAN JOURNAL OF CANCER

Review on Quality of Life Issues in Patients with Primary Brain Tumors

(2010) M. J. B. Taphoorn et al.   ONCOLOGIST

The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials

(2008) Carolyn C. Gotay et al.   JOURNAL OF CLINICAL ONCOLOGY